Drug Price Trends for NDC 70000-0607

Average Pharmacy Cost for 70000-0607

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 70000-0607

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 70000-0607

Last updated: February 20, 2026

What is NDC 70000-0607?

NDC 70000-0607 is the National Drug Code (NDC) identifier for Xyrem (sodium oxybate), used primarily to treat narcolepsy with cataplexy. It is marketed by Jazz Pharmaceuticals. As a Schedule III controlled substance, Xyrem has specific regulatory and pricing complexities.

Market Overview

Market Size and Penetration

• The US narcolepsy market encompasses approximately 135,000 patients nationwide, with an estimated 70% diagnosed and treated.
• Xyrem holds roughly 60% market share within narcolepsy treatments, with annual sales exceeding $800 million as of 2022 (IQVIA, 2022).

Competitors

• Pitolisant (Wakix): Approved for narcolepsy, but with lower market penetration.
• Modafinil and Armodafinil (Provigil, Nuvigil): Off-label use, competing with Xyrem in wakefulness promotion.
• New entrants and generics: No generics available yet; patent expiry is projected post-2024.

Regulatory Status

• Approved by the FDA since 2002.
• Schedule III designation complicates prescribing and insurance reimbursement policies.
• Pregnancy category C, with contraindications for sleep apnea and CNS depression.

Pricing Trends and Projections

Current Price Structure

• Average wholesale price (AWP): approximately $1,300 per 300 mL, 10 mg/mL formulation (First Databank, 2023).
• Patient out-of-pocket costs (OOP): $350–$500 monthly, after insurance adjustments.
• Estimated gross revenue for Jazz Pharmaceuticals: $850–$900 million annually.

Historical Price Trends

Year	Average Wholesale Price (AWP) per 300 mL	Notes
2018	$1,250	Slight increase from previous years
2020	$1,300	Price stabilization
2022	$1,320	Minor price increase

Price Drivers

• Limited competition due to patent protections and regulatory exclusivity.
• Manufacturing complexity and strict storage/control regulations.
• Reimbursement policies and insurance coverage impact net pricing.

Future Price Projections

• Short-term (1-2 years): Prices are expected to stay stable barring regulatory or patent changes. Managed care contracts may influence patient OOP costs.
• Mid-term (3-5 years): Potential for slight decreases if generic competitors enter post-patent expiry or if biosimilars develop.
• Long-term (beyond 5 years): Price reductions could occur if additional indications are approved, expanding market size, or if biosimilars enter the market.

Market Risks and Opportunities

Risks

• Entry of generics after patent expiration.
• Regulatory changes impacting controlled substance scheduling.
• Competition from oral solutions with alternative formulations.

Opportunities

• Expansion into new indications, such as alcohol dependence or fibromyalgia.
• Development of combination therapies.
• Geographic expansion outside the US.

Key Takeaways

• NDC 70000-0607 (Xyrem) commands a high, stable price with minimal near-term risk of price erosion.
• The crowded narcolepsy market and regulatory controls restrict rapid price decrease.
• Patent and exclusivity protections will persist until at least 2024, delaying generic entry.
• Revenue projections remain robust, with slight potential downward adjustments upon patent expiry.
• Future growth hinges on innovative indications, market expansion, and potential biosimilar developments.

FAQs

1. When will generic versions of Xyrem become available?
   Patent protections expire around 2024, after which generics are legally permissible.

2. How does Schedule III classification influence pricing?
   It limits prescribing to certified providers, impacts insurance reimbursement, and maintains higher prices due to regulatory hurdles.

3. Are biosimilar alternatives under development?
   Not currently; biosimilars are more common for biologics than small molecules like sodium oxybate.

4. What are the key factors affecting Xyrem's future pricing?
   Patent status, regulatory environment, market competition, and expansion into new markets or indications.

5. Could stricter regulatory policies reduce prices?
   Possible, if new regulations limit access or increase manufacturing costs, but current policies are stable.

---

References

[1] IQVIA. (2022). Pharmaceutical Market Reports.

[2] First Databank. (2023). Drug Pricing Data.

[3] U.S. Food and Drug Administration. (2022). FDA Drug Approvals and Regulatory Status.